Article

Next-Generation Digital Polymerase Chain Reaction Assay for BCR::ABL1 in Chronic Myeloid Leukemia: Comprehensive Validation Enabling Standardized Measurable Residual Disease Detection

2026-06-02

Abstract excerpt

<title>Abstract</title> <p> <bold>Background</bold> To address the limited sensitivity of quantitative reverse transcription polymerase chain reaction (RT‑qPCR) for measurable residual disease (MRD) in deep molecular response chronic myeloid leukemia (CML), this study validated a digital PCR (dPCR) assay (LQ Check BCR::ABL1 Major %IS Kit) for sensitive MRD quantification and treatment‑free remission (TFR) suppo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f4e632e8-46e0-5553-b583-6306aacb169d
DOI: 10.21203/rs.3.rs-9677261/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Next-Generation Digital Polymerase Chain Reaction Assay for BCR::ABL1 in Chronic Myeloid Leukemia: Comprehensive Validation Enabling Standardized Measurable Residual Disease DetectionDOI 10.21203/rs.3.rs-9677261/v1Read

Analytical Performance Evaluation of a Digital Real‐Time PCR for Quantifying Major BCR :: ABL1 TranscriptsSemantic proximity Read

Digital PCR for BCR‐ABL1 Quantification in CML: Current Applications in Clinical PracticeSemantic proximity Read

Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE studySemantic proximity Read

RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid LeukemiaSemantic proximity Read

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assaySemantic proximity Read

Novel Multiplex Droplet Digital PCR Assays to Monitor Minimal Residual Disease in Chronic Myeloid Leukemia Patients Showing Atypical BCR-ABL1 TranscriptsSemantic proximity Read

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent AdvancesSemantic proximity Read

Comparison of Droplet Digital PCR versus qPCR Measurements on the International Scale for the Molecular Monitoring of Chronic Myeloid Leukemia Patients.Semantic proximity Read

Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR)Semantic proximity Read

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia PatientsSemantic proximity Read

Application of droplet digital PCR in minimal residual disease monitoring of rare fusion transcripts and mutations in haematological malignanciesSemantic proximity Read